TP53 and ovarian carcinoma: In the present study we found that, in contrast to SAHA, novel HDACi (ST2785 and ST3595) and paclitaxel synergistically inhibit the proliferation of ovarian carcinoma cells with wild-type p53, and dramatically activated apoptosis.